Valbiotis S.A.
ALVAL.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.37M
Close$
Share Statistics
| Market cap | $21.37 Million |
|---|---|
| Enterprise Value | $19.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.4 |
| Beta | -0.2 |
| Outstanding Shares | 23,694,000 |
Return
| Return on Equity | -279.30% |
|---|---|
| Return on Assets | -135.13% |
| Return on Invested Capital | -188.64% |
Valuation & Multiples
| P/E Ratio | -1.23 |
|---|---|
| PEG | 4.72 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 17.82 |
| Enterprise Value to EBIT | -1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.94 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.30 M
Average shareholder expectationNext Earnings Call
Expected Date
March 17, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$864,796
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Valbiotis S.A.
50 employees
CEO: Sebastien Peltier Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovasc...